Article

Chronic Low Back Pain Drug Is Abuse-Resistant

Author(s):

Purdue Pharma L.P. has developed an abuse-resistant drug to treat chronic low back pain.

An abuse-resistant opioid analgesic, hydrocodone bitartrate, has been successfully developed to combat chronic low back pain, according to a statement from Purdue Pharma L.P.

In a phase 3 study, scientists evaluated 588 opioid-naïve and opioid-experienced patients with moderate to severe chronic low back pain for 12 weeks. The weekly average score for pain was 7.4 on a scale of 0-10 (10 being maximum pain). The drug dosage was increased once every 3-5 days if necessary until a stabilized once-daily dose was identified (20-120 mg).

A majority of the study’s participants demonstrated at least a 30% improvement of pain intensity and almost half of patients reached 50% improvement. Common side effects after taking the drug were common opioid analgesic side effects including constipation, nausea, vomiting, dizziness, and headache.

Hydrocodone bitartrate contains properties intended to make the tablets harder to manipulate for snorting and intravenous injection purposes.

Purdue Pharma intends to file a New Drug Application with the US Food and Drug Administration later in 2014 requesting approval to market the drug.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.